摘要
目的探讨乳腺癌分子分型在乳腺癌新辅助化疗疗效和预后中的预测作用。方法选取2012年9月至2015年8月间广西玉林市红十字会医院接受新辅助化疗的乳腺癌患者68例,采用免疫组化法进行乳腺癌分子分型,分为HER-2过表达组(11例),Luminal A组(22例),Luminal B组(23例)和三阴性组(12例)。观察4组患者的新辅助化疗疗效,化疗后均随访12个月,统计四组患者的无病生存率。结果三阴性组患者新辅助化疗有效率为83.4%,与HER-2过表达组患者的72.7%比较,差异无统计学意义(P>0.05),但两组均明显高于Luminal A组和Luminal B组患者,差异均有统计学意义(P<0.05)。Luminal A组和Luminal B组患者新辅助化疗有效率分别为68.2%和69.6%,两组比较差异无统计学意义(P>0.05)。随访12个月,Luminal A组和Luminal B组患者的无病生存率均较HER-2过表达组和三阴性组患者高,差异均有统计学意义(P<0.05),其中Luminal A组患者的无病生存率最高,三阴性组患者无病生存率最低。结论不同分子分型乳腺癌患者的新辅助化疗疗效和预后均有自身的特征,临床可将乳腺癌患者的分子分型作为预测新辅助化疗疗效和预后的参考指标之一。
Objective To analyze the prognostic role of molecular typing of breast cancer in neoadjuvant chemotherapy for breast cancer. Methods 68 patients with breast cancer who underwent neoadjuvant chemotherapy in our hospital from September 2012 to August 2015 were enrolled in the study. The patients were divided into four molecular subtypes by immunohistochemistry（ HER-2 overexpression 11 cases,Luminal A 22 cases,Luminal B 23 cases,triple negative 12 cases）. Four groups of patients were followed up for 12 months after chemotherapy. The disease-free survival and overall survival of the four groups were observed rate. Results The neoadjuvant chemotherapy was effective in 83. 4% of neoadjuvant chemotherapy patients and 72. 7% of patients in HER-2 overexpression group（ P 〉 0. 05）,but the two groups were significantly higher than those in Luminal A group and Luminal B group（ P 〈 0. 05）. The effective rates of neoadjuvant chemotherapy in Luminal A and Luminal B patients were 68. 2% and 69. 6%,respectively.There was significant difference between the two groups（ P 〈 0. 05）. The Luminal A group and Luminal B group had higher disease-free survival and overall survival than those in the HER-2 overexpressing group and the triple negative group（ P 〈 0. 05）. The disease-free survival rate of Luminal A group,The highest overall survival rate,triple-negative patients with disease-free survival,the lowest overall survival rate. Conclusions Neoadjuvant chemotherapy and prognosis of patients with different breast cancer molecular typing have their own characteristics. The molecular typing of breast cancer patients can be regarded as one of the reference indexes for predicting the curative effect and prognosis of neoadjuvant chemotherapy
出处
《中国肿瘤临床与康复》
2016年第12期1431-1433,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
乳腺肿瘤
分子分型
药物疗法
治疗结果
预后
预测
Breast neoplasms
Analysis typing
Drug therapy
Treatment outcome
Prognosis
Predictive
